• PN: A211125T

COMPONENTS

45x Ab-conjugated beads (S4P9 - mouse IL-12/IL-23p40 Ab-bead). PN: A211125TA. One vial containing 35 µL of anti-mouse IL-12/IL-23p40 conjugated to AimPlex Bead S4P9.

25x Biotin-detection Ab (Mouse IL-12/IL-23p40 Biotin-dAb). PN: A211125TB. One vial containing 35 µL of biotinylated anti-mouse IL-12/IL-23p40.

Lyophilized Standard Mix - Group 2 Panel A, 10-Plex. PN: MG2009A. One vial containing lyophilized recombinant mouse IL-1β, IL-3, IL-5, IL-7, IL-12/IL-23p40, IL-13, IL-15, IL-17F, IL-21, and IL-22.  Note: If multiple analyte kits on the above target list are ordered as a panel, only one vial of standard mix is supplied for those analyte kits.

STORAGE:  2-8 C in the dark.

IMPORTANT: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.

APPLICATION: Optimal antibody pair and antigen standard for assaying human Mouse IL-12/IL-23p40. Can be multiplexed with other analytes in Mouse Group 2. To be used in conjunction with the AimPlex Mouse/Rat Basic Kit (PN: P200201T) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.

For Research Use Only.  Not for use in diagnostic procedures.

Assay Specifications:

Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate

Sensitivity (LOD): < 5 pg/mL

Quantitation range:

LLOQ: < 10 pg/mL

ULOQ: > 5,000 pg/mL

Standard dose recovery: 70-130%

Intra-assay CV: < 10%

Inter-assay CV: < 20%

Cross-reactivity of analytes in Human Group 2: Negligible

Sample volume: 15 µL/test

Description:

Interleukin 12 (IL-12) is an interleukin that is naturally produced by dendritic cells, macrophages, neutrophils, and human B-lymphoblastoid cells in response to antigenic stimulation. IL-12 is secreted by activated B lymphocytes, dendritic cells and macrophages as a 70 kD heterodimeric glycoprotein comprised of disulfide-bonded 35 kD and 40 kD subunits (IL-12 p70). The p40 is also a subunit of bioactive IL-23 when it is associated with IL-23 p19 subunit. IL-12 plays an important role in the activities of natural killer cells and T lymphocytes. IL-12 mediates enhancement of the cytotoxic activity of NK cells and CD8+ cytotoxic T lymphocytes. There also seems to be a link between IL-2 and the signal transduction of IL-12 in NK cells. IL-12 also has anti-angiogenic activity, which means it can block the formation of new blood vessels by increasing production of interferon gamma, which in turn increases the production of the chemokine inducible protein-10 (IP-10 or CXCL10), which mediates this anti-angiogenic effect. Because of its ability to induce immune responses and its anti-angiogenic activity, there has been an interest in testing IL-12 as a possible anti-cancer drug.

References:

1.      Kaliński P, Hilkens CM, Snijders A, Snijdewint FG, Kapsenberg ML (1997). "IL-12-deficient dendritic cells, generated in the presence of prostaglandin E2, promote type 2 cytokine production in maturing human naive T helper cells". J. Immunol. 159 (1): 28–35. PMID 9200435.

2.      Hsieh CS, Macatonia SE, Tripp CS, Wolf SF, O'Garra A, Murphy KM (April 1993). "Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages". Science 260 (5107): 547–9. doi:10.1126/science.8097338. PMID 8097338.

3.      Wang KS, Frank DA, Ritz J (May 2000). "Interleukin-2 enhances the response of natural killer cells to interleukin-12 through up-regulation of the interleukin-12 receptor and STAT4". Blood 95 (10): 3183–90. PMID 10807786.

4.      van de Veerdonk FL, Plantinga TS, Hoischen A, Smeekens SP, Joosten LA, Gilissen C, Arts P, Rosentul DC, Carmichael AJ, Smits-van der Graaf CA, Kullberg BJ, van der Meer JW, Lilic D, Veltman JA, Netea MG (2011). "STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis". N. Engl. J. Med. 365 (1): 54–61. doi:10.1056/NEJMoa1100102. PMID 21714643.